Novartis to Develop Treatments for Eye, Blood Disorders Using Homology's AAV Gene-Editing Platform

Novartis will use Homology Medicines’ proprietary adeno-associated virus (AAV) gene-editing platform technology to develop new treatments for select ophthalmic targets and a hemoglobinopathy disease, the companies said today.Under a research and development collaboration whose value was not disclosed, Novartis will work with Homology to adapt and refine its gene-editing technology for the treatment of a blood disorder and certain eye diseases, all unspecified. Researchers from Novartis and